VistaGen Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for central nervous system (CNS) disorders, including anxiety and depression. Their lead candidate, fasedienol (PH94B), has shown promise in Phase 3 trials for social anxiety disorder (SAD), a condition affecting over 30 million adults in the U.S., with no FDA-approved acute treatments currently available.Read more